Header Logo
Last Name

Dr Timothy Wells

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Van Voorhis WC, Hooft van Huijsduijnen R, Wells TN. Profile of William C. Campbell, Satoshi Omura, and Youyou Tu, 2015 Nobel Laureates in Physiology or Medicine. Proc Natl Acad Sci U S A. 2015 Dec 29; 112(52):15773-6. PMID: 26699511; PMCID: PMC4702971.
    2. Huston CD, Spangenberg T, Burrows J, Willis P, Wells TN, van Voorhis W. A Proposed Target Product Profile and Developmental Cascade for New Cryptosporidiosis Treatments. PLoS Negl Trop Dis. 2015 Oct; 9(10):e0003987. PMID: 26447884; PMCID: PMC4598153.
    3. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015 Jun; 14(6):424-42. PMID: 26000721.
      View in: PubMed
    4. Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, Wells TN, Spangenberg T, Keiser J. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis. 2014; 8(1):e2610. PMID: 24416463; PMCID: PMC3886923.
    5. Robertson MN, Ylioja PM, Williamson AE, Woelfle M, Robins M, Badiola KA, Willis P, Olliaro P, Wells TN, Todd MH. Open source drug discovery - a limited tutorial. Parasitology. 2014 Jan; 141(1):148-57. PMID: 23985301; PMCID: PMC3884843.
    6. Wells TN. Discovering and developing new medicines for malaria control and elimination. Infect Disord Drug Targets. 2013 Aug; 13(4):292-302. PMID: 24304355.
      View in: PubMed
    7. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, Willis P. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One. 2013; 8(6):e62906. PMID: 23798988; PMCID: PMC3684613.
    8. Burrows JN, van Huijsduijnen RH, Möhrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013 Jun 06; 12:187. PMID: 23742293; PMCID: PMC3685552.
    9. Severin IC, Soares A, Hantson J, Teixeira M, Sachs D, Valognes D, Scheer A, Schwarz MK, Wells TN, Proudfoot AE, Shaw J. Glycosaminoglycan analogs as a novel anti-inflammatory strategy. Front Immunol. 2012; 3:293. PMID: 23087686; PMCID: PMC3472544.
    10. Anthony MP, Burrows JN, Duparc S, Moehrle JJ, Wells TN. The global pipeline of new medicines for the control and elimination of malaria. Malar J. 2012 Sep 07; 11:316. PMID: 22958514; PMCID: PMC3472257.
    11. Wells TN. Natural products as starting points for future anti-malarial therapies: going back to our roots? Malar J. 2011 Mar 15; 10 Suppl 1:S3. PMID: 21411014; PMCID: PMC3059461.
    12. Burrows JN, Chibale K, Wells TN. The state of the art in anti-malarial drug discovery and development. Curr Top Med Chem. 2011; 11(10):1226-54. PMID: 21401508.
      View in: PubMed
    13. Wells TN. Microbiology. Is the tide turning for new malaria medicines? Science. 2010 Sep 03; 329(5996):1153-4. PMID: 20813940.
      View in: PubMed
    14. Tanino Y, Coombe DR, Gill SE, Kett WC, Kajikawa O, Proudfoot AE, Wells TN, Parks WC, Wight TN, Martin TR, Frevert CW. Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs. J Immunol. 2010 Mar 01; 184(5):2677-85. PMID: 20124102; PMCID: PMC4113427.
    15. Déruaz M, Frauenschuh A, Alessandri AL, Dias JM, Coelho FM, Russo RC, Ferreira BR, Graham GJ, Shaw JP, Wells TN, Teixeira MM, Power CA, Proudfoot AE. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med. 2008 Sep 01; 205(9):2019-31. PMID: 18678732; PMCID: PMC2526197.
    16. Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, Riva S, Mack M, Déruaz M, Borlat F, Vitte PA, Wells TN, Teixeira MM, Proudfoot AE. An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol. 2008 Oct; 84(4):1101-8. PMID: 18662971; PMCID: PMC2538597.
    17. Ojo KK, Gillespie JR, Riechers AJ, Napuli AJ, Verlinde CL, Buckner FS, Gelb MH, Domostoj MM, Wells SJ, Scheer A, Wells TN, Van Voorhis WC. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 Oct; 52(10):3710-7. PMID: 18644955; PMCID: PMC2565902.
    18. Frauenschuh A, Power CA, Déruaz M, Ferreira BR, Silva JS, Teixeira MM, Dias JM, Martin T, Wells TN, Proudfoot AE. Molecular cloning and characterization of a highly selective chemokine-binding protein from the tick Rhipicephalus sanguineus. J Biol Chem. 2007 Sep 14; 282(37):27250-8. PMID: 17640866.
      View in: PubMed
    19. Culley FJ, Pennycook AM, Tregoning JS, Dodd JS, Walzl G, Wells TN, Hussell T, Openshaw PJ. Role of CCL5 (RANTES) in viral lung disease. J Virol. 2006 Aug; 80(16):8151-7. PMID: 16873271; PMCID: PMC1563837.
    20. Kadi L, Selvaraju R, de Lys P, Proudfoot AE, Wells TN, Boschert U. Differential effects of chemokines on oligodendrocyte precursor proliferation and myelin formation in vitro. J Neuroimmunol. 2006 May; 174(1-2):133-46. PMID: 16574247.
      View in: PubMed
    21. Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers--therapeutics in the making? Trends Pharmacol Sci. 2006 Jan; 27(1):41-7. PMID: 16310864.
      View in: PubMed
    22. Johnson Z, Schwarz M, Power CA, Wells TN, Proudfoot AE. Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol. 2005 May; 26(5):268-74. PMID: 15866240.
      View in: PubMed
    23. Johnson Z, Kosco-Vilbois MH, Herren S, Cirillo R, Muzio V, Zaratin P, Carbonatto M, Mack M, Smailbegovic A, Rose M, Lever R, Page C, Wells TN, Proudfoot AE. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol. 2004 Nov 01; 173(9):5776-85. PMID: 15494530.
      View in: PubMed
    24. Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, Roulin K, Harrenga A, Wells TN, Proudfoot AE. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure. 2004 Nov; 12(11):2081-93. PMID: 15530372.
      View in: PubMed
    25. Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol. 2003 Nov 15; 171(10):5498-506. PMID: 14607956.
      View in: PubMed
    26. Field J, Marshall AC, Hertzog PJ, Wells TN, Alderuccio F, Toh BH. Chemokine receptor CCR5 is not required for development of experimental autoimmune gastritis. Clin Immunol. 2003 Nov; 109(2):238-47. PMID: 14597223.
      View in: PubMed
    27. Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A, Wells TN, Wight TN, Martin TR. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol. 2003 Apr; 28(4):464-72. PMID: 12654635.
      View in: PubMed
    28. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TN, Kosco-Vilbois MH. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1885-90. PMID: 12571364; PMCID: PMC149928.
    29. Proudfoot AE, Power CA, Rommel C, Wells TN. Strategies for chemokine antagonists as therapeutics. Semin Immunol. 2003 Feb; 15(1):57-65. PMID: 12495641.
      View in: PubMed
    30. Falcão PL, Correa-Oliveira R, Fraga LA, Talvani A, Proudfoot AE, Wells TN, Williams TJ, Jose PJ, Teixeira MM. Plasma concentrations and role of macrophage inflammatory protein-1alpha during chronic Schistosoma mansoni infection in humans. J Infect Dis. 2002 Dec 01; 186(11):1696-700. PMID: 12447751.
      View in: PubMed
    31. Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov. 2002 May; 1(5):347-58. PMID: 12120410.
      View in: PubMed
    32. Frevert CW, Goodman RB, Kinsella MG, Kajikawa O, Ballman K, Clark-Lewis I, Proudfoot AE, Wells TN, Martin TR. Tissue-specific mechanisms control the retention of IL-8 in lungs and skin. J Immunol. 2002 Apr 01; 168(7):3550-6. PMID: 11907118.
      View in: PubMed
    33. Wells TN, Proudfoot AE. Chemokine receptors and their antagonists in allergic lung disease. Inflamm Res. 1999 Jul; 48(7):353-62. PMID: 10450784.
      View in: PubMed
    34. Wells TN, Proudfoot AE, Power CA. Strategies to interfere with the chemokine network in disease. Chem Immunol. 1999; 72:181-201. PMID: 10550937.
      View in: PubMed
    35. Wells TN, Proudfoot AE, Power CA. Chemokine receptors and their role in leukocyte activation. Immunol Lett. 1999 Jan; 65(1-2):35-40. PMID: 10065624.
      View in: PubMed
    Wells's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description